Genome&Company
A drug developer building ADC and immuno-oncology pipelines on its GNOCLE™ platform, alongside microbiome cosmetics and CDMO businesses.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2015 and listed on KOSDAQ in 2020, Genome & Company is a drug development specialist built on its GNOCLE™ platform, advancing ADC and immuno-oncology pipelines targeting novel antigens. Its novel-target immuno-oncology candidate GENA-104 (EP0089) was licensed to UK-based Ellipses Pharma Limited in February 2025, and its novel-target ADC antibody Debio 0633 was licensed to Debiopharm in June 2024, while the company also runs a consumer business through its microbiome skincare brand UIQ and probiotic IMMUNOVA GEN001. It additionally operates a CDMO business through List Biological Laboratories, a US microbiome CDMO acquired in September 2021, with revenue drawn from licensing income, cosmetics sales, and biopharmaceutical contract manufacturing.
Products & technology
- GENA-104 (EP0089)Novel-target (CNTN4) immuno-oncology antibody candidate
- Debio 0633Novel-target antibody for ADC development
- GENA-104 ADCCNTN4-targeting antibody-drug conjugate candidate
- UIQMicrobiome skincare brand containing Cutibiome, Reliefbiome, Rejubiome ingredients
- IMMUNOVA GEN001Medical-grade probiotic based on strain GEN-001
Clinical trials
data.go.kr3 MFDS clinical trial authorisations · 2020–2022 (Phase 2 2 · Phase 1 1)
- Phase 2GEN-0012022-11-07
8 trial sites
- Phase 2GEN-0012021-10-08
5 trial sites
- Phase 1GEN-0012020-11-09
1 trial site
R&D and key agreements
Source: DART corporate disclosureGENA-104(EP0089) · 면역항암(CNTN4 표적) · 라이선시(엘립시스 파마) 임상1상 · IND approved in Korea Jan 2024; published in Science Immunology Oct 2024; presented at AACR 2025
Debio 0633 · ADC(신규타깃) · 디바이오팜 개발 중 · Combined with Debiopharm's proprietary Multilink technology for ADC development
GENA-104 ADC · CNTN4 표적 ADC · 전임상(PDX 평가 중) · Exatecan (Topo1 inhibitor)-conjugated candidate showed antitumor efficacy in mouse CDX model
GENA-120 · 신규타깃(ITGB4) ADC · Source text is truncated mid-sentence; details unavailable
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition